TrialsgrambetaRCTs are beautiful

AMBITION

2015

Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension

In 500 patients with pulmonary arterial hypertension, initial ambrisentan plus tadalafil reduced clinical-failure events compared with monotherapy.

Result

Efficacy: First clinical-failure eventHR 0.5

Below 1 favours ambrisentan plus tadalafil, above 1 favours monotherapy.

Original publication
Subtopic
Combination therapy
Design
Double-blind RCT
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Galiè N, et al. N Engl J Med. 2015;373(9):834-844.doi 10.1056/NEJMoa1413687

Discussion & critique

Established upfront dual combination therapy as the standard initial approach for most patients with PAH.